Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
PDRadiopharma’s PET Imaging Agent Amyvid Widens Label Too
PDRadiopharma said on September 3 that its amyloid PET imaging agent Amyvid Injection (florbetapir (18F)) has expanded the label for use in patients being treated with anti-amyloid beta (Aβ) antibodies. The product was approved on August 29 for the indication…
To read the full story
Related Article
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
- PET Agent Vizamyl Approved for Use in Patients on Anti-Aβ Therapy
September 3, 2024
- As Leqembi Listing Approaches, Chuikyo OKs Coverage for PET Device and Diagnostics
November 27, 2023
- 2 Amyloid PET Imaging Agents Expand Labels as Lecanemab Approval Nears
September 1, 2023
BUSINESS
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Samsca Generics Extend Label to ADPKD
April 21, 2026
- ASKA Ups Stake in MedChoice Parent to Deepen Philippines Tie-Up
April 21, 2026
- Nxera Bags US$10 Million Milestone from AbbVie in Neuro Collaboration
April 21, 2026
- Asahi Kasei Closes Aicuris Buy, Eyes US$500 Million Sales by 2030
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…